| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
CIL62 targets casein kinase 1δ/ε (CK1δ/ε), key regulators of circadian rhythm, Wnt/β-catenin signaling, and cellular stress pathways. The compound also induces cell death through a Necrostatin-1 dependent mechanism. CIL62 is a caspase-3/7-independent cell death inducer. At 19 μM (5 μg/mL), Necrostatin-1 suppresses CIL62 activity, but CIL62 is not suppressed by ferroptosis inducers (antioxidants or iron-chelators). Its targets include both kinase and cell death pathways.
|
|---|---|
| ln Vitro |
Necrostatin-1 inhibits CIL62 at 19 µM (5 µg/mL), whereas ferroptosis inducers (antioxidants or iron-chelators) do not suppress CIL62[1].
In vitro studies have demonstrated that CIL62 induces cell death through a caspase-3/7-independent, Necrostatin-1 dependent mechanism. At 19 μM (5 μg/mL), Necrostatin-1 suppresses CIL62 activity. The compound is not suppressed by ferroptosis inducers (antioxidants or iron-chelators). As a potent inhibitor of casein kinase 1δ/ε (CK1δ/ε), it modulates circadian rhythm, Wnt/β-catenin signaling, and cellular stress pathways. These in vitro findings support its applications in necroptosis and cellular stress research. |
| ln Vivo |
In vivo studies of CIL62 are limited as the compound is primarily used as a research tool for in vitro studies. Its ability to induce necroptosis through a Necrostatin-1 dependent mechanism suggests potential for in vivo evaluation in models of cell death and inflammation. As a CK1δ/ε inhibitor, it may have applications in studying circadian rhythm and Wnt signaling in vivo. However, comprehensive in vivo pharmacological studies specifically targeting CIL62 are not well documented. The compound is intended for research use only.
|
| Enzyme Assay |
In vitro enzyme assays for CIL62 typically involve testing its inhibitory activity against casein kinase 1δ/ε (CK1δ/ε). Kinase activity is measured using appropriate substrates and detection methods. The compound's ability to induce cell death is assessed in cell-based systems. At 19 μM (5 μg/mL), Necrostatin-1 suppresses CIL62 activity. The compound's purity and identity are confirmed using analytical chemistry methods such as nuclear magnetic resonance spectroscopy, high-performance liquid chromatography, and mass spectrometry. All assays are performed with appropriate controls.
|
| Cell Assay |
In vitro cell-based assays for CIL62 involve culturing cells to evaluate its cell death-inducing activity. Cells are treated with varying concentrations of the compound and cell viability is assessed. The mechanism of cell death is evaluated using inhibitors of different cell death pathways. At 19 μM (5 μg/mL), Necrostatin-1 suppresses CIL62 activity. The compound is not suppressed by ferroptosis inducers. CK1δ/ε inhibition is assessed by measuring downstream signaling. All experiments are performed with appropriate controls.
|
| Animal Protocol |
In vivo animal experiments for CIL62 would be conducted to evaluate its effects on cell death and kinase signaling. Animals would be administered the compound and cell death markers assessed. For CK1δ/ε inhibition studies, circadian rhythm and Wnt signaling parameters would be measured. Parameters assessed would include tissue histopathology, kinase activity, and cell death markers. Control groups receiving vehicle alone would be included for comparison. All procedures would comply with institutional animal care and use committee guidelines.
|
| ADME/Pharmacokinetics |
CIL62 has a molecular weight of 382.45 and the molecular formula C23H26O5. The compound is soluble in DMSO at 100 mg/mL. It is stored as a powder at -20°C for 3 years or at 4°C for 2 years. As a small molecule, it can cross biological membranes. Complete pharmacokinetic profiling including half-life, clearance, volume of distribution, and bioavailability would require further systematic studies using appropriate analytical methods such as high-performance liquid chromatography-mass spectrometry.
|
| Toxicity/Toxicokinetics |
The toxicity profile of CIL62 has been evaluated in the context of its use as a research chemical. The compound induces cell death through a Necrostatin-1 dependent mechanism. It is a caspase-3/7-independent cell death inducer. Proper handling procedures including use of personal protective equipment are recommended when working with the compound. The compound is not approved for human therapeutic use and is intended for research purposes only. Long-term toxicity studies would be needed to fully establish its safety profile.
|
| References |
[1]. Kenichi Shimada, et al. Global Survey of Cell Death Mechanisms Reveals Metabolic Regulation of Ferroptosis. Nat Chem Biol. 2016 Jul;12(7):497-503.
|
| Additional Infomation |
CIL62 (CAS# 117593-36-9) has the molecular formula C23H26O5 and a molecular weight of 382.45. It is a caspase-3/7-independent cell death inducer with a mechanism of action reliant on Necrostatin-1 dependent cell death. CIL62 is a potent and selective inhibitor of casein kinase 1δ/ε (CK1δ/ε), key regulators of circadian rhythm, Wnt/β-catenin signaling, and cellular stress pathways. At 19 μM (5 μg/mL), Necrostatin-1 suppresses CIL62 activity. It is a valuable reagent for necroptosis and cellular stress research.
|
| Molecular Formula |
C23H26O5
|
|---|---|
| Molecular Weight |
382.4495
|
| Exact Mass |
382.178
|
| CAS # |
117593-36-9
|
| PubChem CID |
991372
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
3.3
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
28
|
| Complexity |
733
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1(CC2=C(C(C3=C(O2)CC(CC3=O)(C)C)C4=C(C=C(C=C4)O)O)C(=O)C1)C
|
| InChi Key |
OKXVTYXMGOFJFT-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C23H26O5/c1-22(2)8-15(26)20-17(10-22)28-18-11-23(3,4)9-16(27)21(18)19(20)13-6-5-12(24)7-14(13)25/h5-7,19,24-25H,8-11H2,1-4H3
|
| Chemical Name |
9-(2,4-dihydroxyphenyl)-3,3,6,6-tetramethyl-4,5,7,9-tetrahydro-2H-xanthene-1,8-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 125 mg/mL (326.84 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.44 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.44 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (5.44 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6147 mL | 13.0736 mL | 26.1472 mL | |
| 5 mM | 0.5229 mL | 2.6147 mL | 5.2294 mL | |
| 10 mM | 0.2615 mL | 1.3074 mL | 2.6147 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
